Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
A Pilot, Dose-Finding, Pharmacodynamic and Pharmacokinetic Study of Orally Administered Botanical Kratom.
Journal: Journal of clinical psychopharmacology
Published: September 29, 2025
A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABAB receptor, and morphine in recreational opioid users.
Journal: Journal of psychopharmacology (Oxford, England)
Published: May 01, 2023
A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder.
Journal: Journal of psychopharmacology (Oxford, England)
Published: February 04, 2023
Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate.
Journal: Current medical research and opinion
Published: May 16, 2022
Particle size affects pharmacokinetics of milled oxycodone hydrochloride tablet products following nasal insufflation in nondependent, recreational opioid users.
Journal: Clinical and translational science
Published: February 16, 2021
Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.
Journal: Sleep
Published: December 04, 2020
Phase I Pharmacokinetic Study of Fixed-Dose Combinations of Ibuprofen and Acetaminophen in Healthy Adult and Adolescent Populations.
Journal: Drugs in R&D
Published: March 05, 2020
Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study.
Journal: Pain medicine (Malden, Mass.)
Published: September 26, 2019
Pharmacokinetics and Abuse Potential of Asalhydromorphone, a Novel Prodrug of Hydromorphone, After Intranasal Administration in Recreational Drug Users.
Journal: Pain medicine (Malden, Mass.)
Published: April 16, 2019
A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior.
Journal: Addiction biology
Published: January 14, 2019
Abuse potential of mirogabalin in recreational polydrug users.
Journal: Therapeutic advances in drug safety
Published: January 04, 2019
A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor.
Journal: Journal of psychopharmacology (Oxford, England)
Published: October 02, 2018
Last Updated: 09/26/2026